Women’s Risk of Colorectal Cancer Linked To Physical Inactivity
NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Inactive and sedentary lifestyles have been consistently linked to both...
NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Inactive and sedentary lifestyles have been consistently linked to both...
VANCOUVER, BC / ACCESSWIRE / March 4, 2019 / EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the "Company") is...
Berlin – From 17 to 21 June 2019, the International Federation of Societies for Surgery of the Hand (IFSSH) and...
BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 4, 2019 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 4, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX & MDAX; Nasdaq:...
VANCOUVER, BC / ACCESSWIRE / March 4, 2019 / EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the "Company") is...
RESEARCH TRIANGLE PARK, NC and NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Adhera Therapeutics (OTCQB: ATRX), a...
Innovative XCART platform with demonstrated proof of mechanism and preclinical evidence of target specificity positions Xenetic to address high value...
AUSTIN, TX / ACCESSWIRE / March 4, 2019 / Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, announced today...
The Company qualifies for reduced or waived fees for medical device submissions with the FDA HOUSTON, TX / ACCESSWIRE /...
TORONTO, ONTRAIO / ACCESSWIRE / March 4, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF),...
TORONTO, ON / ACCESSWIRE / March 4, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellipharmaceutics" or the "Company"),...
REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments...
WALTHAM, MA / ACCESSWIRE / March 1, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (''EyeGate'' or ''the Company'') today announced...
TORONTO, ON / ACCESSWIRE / February 27, 2019 / Itoco Inc (OTC PINK: ITMC), has signed a letter of intent...
- Preliminary data suggests the addition of HS-110 to Nivolumab may restore responsiveness to treatment after tumor progression on prior...
Uses proprietary chemoprobe technology to demonstrate target engagement, key to drug development and rational dosing Useful to identify interaction partners...
PHASE II CLINICAL TRIAL ON PERSISTENT CHRONIC COUGH HAMBURG, GERMANY / ACCESSWIRE / February 28, 2019 / Evotec AG (OTC...
Theralase Achieves Third Place in the Clean Technology and Life Sciences Category on the 2019 TSX Venture 50 TM TORONTO,...
VANCOUVER, BC / ACCESSWIRE / February 28, 2019 / EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the ''Company'') provides...